Dr. O'Connor on Acalabrutinib Versus Ibrutinib in MCL

Owen O'Connor, MD, PhD
Published: Wednesday, Jan 03, 2018



Owen O'Connor, MD, PhD, professor of medicine and experimental therapeutics, director of the Center for Lymphoid Malignancies, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses acalabrutinib (Calquence) versus ibrutinib (Imbruvica) for the treatment of patients with mantle cell lymphoma (MCL).

Acalabrutinib is seen to be a cleaner, more selective BTK inhibitor, says O’Connor. It hits fewer kinases than ibrutinib, which could mean better tolerability, he adds.
 


Owen O'Connor, MD, PhD, professor of medicine and experimental therapeutics, director of the Center for Lymphoid Malignancies, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses acalabrutinib (Calquence) versus ibrutinib (Imbruvica) for the treatment of patients with mantle cell lymphoma (MCL).

Acalabrutinib is seen to be a cleaner, more selective BTK inhibitor, says O’Connor. It hits fewer kinases than ibrutinib, which could mean better tolerability, he adds.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Management of Adverse Events Associated with Therapies for Hematological Disorders: Nurses' PerspectiveApr 21, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x